{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:03:38Z","timestamp":1791475418040,"version":"4.3.4"},"reference-count":311,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.bbcan.2015.08.002","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T22:15:52Z","timestamp":1439936152000},"page":"189-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":471,"title":["Lung cancer: Biology and treatment options"],"prefix":"10.1016","volume":"1856","author":[{"given":"Hassan","family":"Lemjabbar-Alaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2950-7465","authenticated-orcid":false,"given":"Omer UI","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2015.08.002_bb0005","series-title":"Cancer Facts & Figures 2014","author":"American-Cancer-Society","year":"2014"},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0010","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2012.46.9270","article-title":"New pathologic classification of lung cancer: relevance for clinical practice and clinical trials","volume":"31","author":"Travis","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb0015","series-title":"TNM Staging Atlas With Oncoanatomy","author":"Rubin","year":"2012"},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0020","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1993.11.2.336","article-title":"Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group","volume":"11","author":"Murray","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2015.08.002_bb0025","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/JTO.0b013e31818b06e3","article-title":"The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM classification for lung cancer","volume":"3","author":"Travis","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0873-2159(15)30110-0","article-title":"The IASLC Lung Cancer Staging Project. Comparing the current 6(th) TNM edition with the proposed 7(th) edition","volume":"15","author":"Carvalho","year":"2009","journal-title":"Rev. Port. Pneumol."},{"issue":"12","key":"10.1016\/j.bbcan.2015.08.002_bb0035","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.rmed.2010.08.005","article-title":"Staging of non-small cell lung cancer (NSCLC): a review","volume":"104","author":"Tsim","year":"2010","journal-title":"Respir. Med."},{"issue":"4260","key":"10.1016\/j.bbcan.2015.08.002_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2015.08.002_bb0045","series-title":"Principles & Practice of Lung Cancer: The Official Reference Text of the IASLC","author":"Pass","year":"2010"},{"issue":"7511","key":"10.1016\/j.bbcan.2015.08.002_bb0050","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2015.08.002_bb0055","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0060","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","article-title":"Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin","volume":"158","author":"Hoadley","year":"2014","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0065","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.18632\/oncotarget.1891","article-title":"Molecular pathways and therapeutic targets in lung cancer","volume":"5","author":"Shtivelman","year":"2014","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.bbcan.2015.08.002_bb0070","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"36","key":"10.1016\/j.bbcan.2015.08.002_bb0075","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5676","key":"10.1016\/j.bbcan.2015.08.002_bb0080","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0085","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/JTO.0b013e31812f3c1a","volume":"2","author":"Goldstraw","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2015.08.002_bb0090","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb0095","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer","volume":"8","author":"Lord","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0091186","article-title":"Ubiquitination and degradation of ribonucleotide reductase M1 by the polycomb group proteins RNF2 and BMI1 and cellular response to gemcitabine","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"issue":"34","key":"10.1016\/j.bbcan.2015.08.002_bb0105","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1200\/JCO.2009.21.9766","article-title":"Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer","volume":"27","author":"Reynolds","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.bbcan.2015.08.002_bb0110","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.2174\/092986710792065054","article-title":"Ribonucleotide reductase: a mechanistic portrait of substrate analogues inhibitors","volume":"17","author":"Perez","year":"2010","journal-title":"Curr. Med. Chem."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0115","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/ijc.22390","article-title":"Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer","volume":"120","author":"Nakahira","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"40","key":"10.1016\/j.bbcan.2015.08.002_bb0120","doi-asserted-by":"crossref","first-page":"9733","DOI":"10.1021\/bi00155a029","article-title":"A model for the role of multiple cysteine residues involved in ribonucleotide reduction: amazing and still confusing","volume":"31","author":"Mao","year":"1992","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.bbcan.2015.08.002_bb0125","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1158\/0008-5472.CAN-03-3363","article-title":"An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines","volume":"64","author":"Davidson","year":"2004","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbrc.2011.08.111","article-title":"Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by n-ethylmaleimide","volume":"413","author":"Chen","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"20","key":"10.1016\/j.bbcan.2015.08.002_bb0135","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1158\/0008-5472.CAN-05-0989","article-title":"In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant","volume":"65","author":"Bergman","year":"2005","journal-title":"Cancer Res."},{"issue":"29","key":"10.1016\/j.bbcan.2015.08.002_bb0140","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1200\/JCO.2006.06.1101","article-title":"RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer","volume":"24","author":"Bepler","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb0145","first-page":"1","article-title":"Sulf2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15","volume":"12","author":"Tessema","year":"2011","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bbcan.2015.08.002_bb0150","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14728222.2010.504718","article-title":"Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate","volume":"14","author":"Rosen","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"issue":"51","key":"10.1016\/j.bbcan.2015.08.002_bb0155","doi-asserted-by":"crossref","first-page":"49175","DOI":"10.1074\/jbc.M205131200","article-title":"Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans","volume":"277","author":"Morimoto-Tomita","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0160","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/onc.2009.365","article-title":"Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis","volume":"29","author":"Lemjabbar-Alaoui","year":"2010","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020351","article-title":"Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer","volume":"6","author":"Dutt","year":"2011","journal-title":"PLoS One"},{"issue":"7417","key":"10.1016\/j.bbcan.2015.08.002_bb0170","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","year":"2012","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.bbcan.2015.08.002_bb0175","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.bbcan.2015.08.002_bb0180","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.bbcan.2015.08.002_bb0185","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1158\/1078-0432.CCR-08-0168","article-title":"EML4\u2013ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer","volume":"14","author":"Koivunen","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.bbcan.2015.08.002_bb0190","doi-asserted-by":"crossref","first-page":"5609","DOI":"10.1158\/1078-0432.CCR-08-2762","article-title":"Inhibition of ALK signaling for cancer therapy","volume":"15","author":"Mosse","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2015.08.002_bb0195","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","article-title":"The biology and treatment of EML4\u2013ALK non-small cell lung cancer","volume":"46","author":"Sasaki","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0200","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4\u2013ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2015.08.002_bb0205","first-page":"146","article-title":"Predictive and prognostic value of ALK gene rearrangement in non-small cell lung cancer","volume":"4","author":"Kulig","year":"2014","journal-title":"Epidemiol"},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0210","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/JTO.0b013e31823c5c32","article-title":"Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma","volume":"7","author":"Yang","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.bbcan.2015.08.002_bb0215","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1002\/cncr.26668","article-title":"Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer","volume":"118","author":"Lee","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0220","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/cncr.26311","article-title":"Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement","volume":"118","author":"Kim","year":"2012","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.bbcan.2015.08.002_bb0225","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4\u2013ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0230","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.bbcan.2015.08.002_bb0235","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10555-011-9279-y","article-title":"Tumor microenvironment is multifaceted","volume":"30","author":"Sautes-Fridman","year":"2011","journal-title":"Cancer Metastasis Rev."},{"issue":"5795","key":"10.1016\/j.bbcan.2015.08.002_bb0245","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.bbcan.2015.08.002_bb0250","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMoa051424","article-title":"Effector memory T cells, early metastasis, and survival in colorectal cancer","volume":"353","author":"Pages","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.bbcan.2015.08.002_bb0255","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1158\/0008-5472.CAN-11-4094","article-title":"Cellular constituents of immune escape within the tumor microenvironment","volume":"72","author":"Kerkar","year":"2012","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb0260","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.4049\/jimmunol.175.7.4583","article-title":"Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells","volume":"175","author":"Kusmartsev","year":"2005","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.bbcan.2015.08.002_bb0265","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1002\/eji.200939892","article-title":"Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions","volume":"39","author":"Bronte","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0270","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0275","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/0008-5472.CAN-09-2587","article-title":"Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine","volume":"70","author":"Srivastava","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0280","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00432-009-0634-0","article-title":"Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11B+\/CD14(\u2212)\/CD15+\/CD33+ myeloid-derived suppressor cells and CD8+ t lymphocytes in patients with advanced-stage non-small cell lung cancer","volume":"136","author":"Liu","year":"2010","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.bbcan.2015.08.002_bb0285","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1158\/1078-0432.CCR-10-2805","article-title":"Prognostic immune markers in non-small cell lung cancer","volume":"17","author":"Suzuki","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0290","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1183\/09031936.00065708","article-title":"Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival","volume":"33","author":"Ohri","year":"2009","journal-title":"Eur. Respir. J."},{"issue":"35","key":"10.1016\/j.bbcan.2015.08.002_bb0295","doi-asserted-by":"crossref","first-page":"8959","DOI":"10.1200\/JCO.2005.01.4910","article-title":"Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer","volume":"23","author":"Welsh","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0300","first-page":"1755","article-title":"Clinical significance of defective dendritic cell differentiation in cancer","volume":"6","author":"Almand","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"3\u20134","key":"10.1016\/j.bbcan.2015.08.002_bb0305","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/08820130600803429","article-title":"Dendritic cells and tumor microenvironment: a dangerous liaison","volume":"35","author":"Fricke","year":"2006","journal-title":"Immunol. Investig."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0310","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jtcvs.2008.05.046","article-title":"Neutrophil\/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer","volume":"137","author":"Sarraf","year":"2009","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0315","first-page":"356","article-title":"PGE(2) contributes to TGF-beta induced t regulatory cell function in human non-small cell lung cancer","volume":"2","author":"Baratelli","year":"2010","journal-title":"Am. J. Transl. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0320","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1378\/chest.117.2.365","article-title":"Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients","volume":"117","author":"De Vita","year":"2000","journal-title":"Chest"},{"issue":"27","key":"10.1016\/j.bbcan.2015.08.002_bb0325","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2007.15.0284","article-title":"Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures","volume":"26","author":"Dieu-Nosjean","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0330","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.critrevonc.2011.12.005","article-title":"Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials","volume":"83","author":"De Pas","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0335","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.semradonc.2010.01.003","article-title":"The tumor microenvironment in non-small-cell lung cancer","volume":"20","author":"Graves","year":"2010","journal-title":"Semin. Radiat. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0340","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0345","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.mcna.2005.02.001","article-title":"Health-related disparities: influence of environmental factors","volume":"89","author":"Olden","year":"2005","journal-title":"Med. Clin. North Am."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0350","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2005.03.7077","article-title":"Lung cancer and race: equal treatment yields equal outcome among equal patients, but there is no equal treatment","volume":"24","author":"Brawley","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0355","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5732\/cjc.011.10106","article-title":"East meets west: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians","volume":"30","author":"Zhou","year":"2011","journal-title":"Chin. J. Cancer"},{"issue":"5 Suppl.","key":"10.1016\/j.bbcan.2015.08.002_bb0360","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.12-2359","article-title":"Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"143","author":"Howington","year":"2013","journal-title":"Chest"},{"issue":"16","key":"10.1016\/j.bbcan.2015.08.002_bb0365","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJM199910143411606","article-title":"Racial differences in the treatment of early-stage lung cancer","volume":"341","author":"Bach","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2015.08.002_bb0370","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-pathol-011110-130206","article-title":"EGFR mutations and lung cancer","volume":"6","author":"da Cunha Santos","year":"2011","journal-title":"Annu. Rev. Pathol."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0375","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1634\/theoncologist.2009-0186","article-title":"Adjuvant therapy in non-small cell lung cancer: current and future directions","volume":"15","author":"Sangha","year":"2010","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0380","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1586\/era.09.11","article-title":"New TNM classification for non-small-cell lung cancer","volume":"9","author":"Tanoue","year":"2009","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"21","key":"10.1016\/j.bbcan.2015.08.002_bb0385","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"9722","key":"10.1016\/j.bbcan.2015.08.002_bb0390","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(10)60059-1","article-title":"Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data","volume":"375","author":"NM-aC","year":"2010","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.bbcan.2015.08.002_bb0395","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.bbcan.2015.08.002_bb0400","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/jnci\/djg059","article-title":"Adjuvant Lung Project Italy\/European Organisation for Research Treatment of Cancer\u2014Lung Cancer Cooperative Group I: randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer","volume":"95","author":"Scagliotti","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"19","key":"10.1016\/j.bbcan.2015.08.002_bb0405","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2004.01.153","article-title":"Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials","volume":"22","author":"Hotta","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0410","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1378\/chest.102.5.1319","article-title":"Photodynamic therapy in the management of early superficial squamous cell carcinoma as an alternative to surgical resection","volume":"102","author":"Edell","year":"1992","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0415","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"International Adjuvant Lung Cancer Trial Collaborative G: cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer","volume":"350","author":"Arriagada","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2015.08.002_bb0420","first-page":"CD002142","article-title":"Postoperative radiotherapy for non-small cell lung cancer","volume":"2","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9577","key":"10.1016\/j.bbcan.2015.08.002_bb0425","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(07)60714-4","article-title":"Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22\/NVALT 2\/EORTC 08012 multicentre randomised trial and update of systematic review","volume":"369","author":"Gilligan","year":"2007","journal-title":"Lancet"},{"issue":"7010","key":"10.1016\/j.bbcan.2015.08.002_bb0430","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1136\/bmj.311.7010.899","article-title":"Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group","volume":"311","year":"1995","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0435","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/annonc\/mdj117","article-title":"Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients","volume":"17","author":"Auperin","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb0440","first-page":"CD002140","article-title":"Concurrent chemoradiotherapy in non-small cell lung cancer","volume":"4","author":"Rowell","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0445","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.athoracsur.2005.03.088","article-title":"Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies","volume":"80","author":"Doddoli","year":"2005","journal-title":"Ann. Thorac. Surg."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0450","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1067\/mtc.2001.112826","article-title":"Chest wall invasion in non-small cell lung carcinoma: a rationale for en bloc resection","volume":"121","author":"Facciolo","year":"2001","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0455","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ejcts.2004.07.038","article-title":"Resection of chest wall invasion in patients with non-small cell lung cancer","volume":"26","author":"Matsuoka","year":"2004","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0460","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1378\/chest.127.4.1136","article-title":"Stage of lung cancer in relation to its size: part 2","volume":"127","author":"Wisnivesky","year":"2005","journal-title":"Evid. Chest"},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0465","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1378\/chest.111.6.1710","article-title":"Revisions in the international system for staging lung cancer","volume":"111","author":"Mountain","year":"1997","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0470","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0475","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2009.21.9618","article-title":"Cetuximab and first-line taxane\/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099","volume":"28","author":"Lynch","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0480","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0485","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0490","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0495","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2012.43.7459","article-title":"Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea","volume":"31","author":"Gerber","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0500","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/sj.bjc.6603383","article-title":"Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer","volume":"95","author":"von Plessen","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0505","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.20.5.1335","article-title":"Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB\/IV non-small-cell lung cancer","volume":"20","author":"Socinski","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0510","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"Paz-Ares","year":"2012","journal-title":"Lancet Oncol."},{"issue":"9699","key":"10.1016\/j.bbcan.2015.08.002_bb0515","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0520","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(10)70112-1","article-title":"Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study","volume":"11","author":"Cappuzzo","year":"2010","journal-title":"Lancet Oncol."},{"issue":"31","key":"10.1016\/j.bbcan.2015.08.002_bb0525","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1200\/JCO.2010.31.8162","article-title":"Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer","volume":"29","author":"Brugger","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0530","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ctrv.2006.07.003","article-title":"Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials","volume":"32","author":"Bria","year":"2006","journal-title":"Cancer Treat. Rev."},{"issue":"10","key":"10.1016\/j.bbcan.2015.08.002_bb0535","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2015.08.002_bb0540","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1200\/JCO.2006.09.8251","article-title":"Individual patient data meta-analysis of docetaxel administered once every 3weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer","volume":"25","author":"Di Maio","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2015.08.002_bb0545","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2015.08.002_bb0550","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.bbcan.2015.08.002_bb0555","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1200\/JCO.2006.06.7835","article-title":"Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer","volume":"24","author":"Weiss","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0560","doi-asserted-by":"crossref","DOI":"10.1097\/01.JTO.0000284677.33344.62","volume":"2","author":"Peterson","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0565","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0570","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1200\/JCO.2004.06.123","article-title":"Hypofractionated palliative radiotherapy (17Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial","volume":"22","author":"Sundstrom","year":"2004","journal-title":"J. Clin. Oncol."},{"issue":"9652","key":"10.1016\/j.bbcan.2015.08.002_bb0575","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.bbcan.2015.08.002_bb0580","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2015.08.002_bb0585","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S1470-2045(11)70232-7","article-title":"Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis","volume":"12","author":"Shaw","year":"2011","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0590","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1097-0142(19950901)76:5<765::AID-CNCR2820760509>3.0.CO;2-E","article-title":"The treatment of patients with recurrent brain metastases. A retrospective analysis of 109 patients with nonsmall cell lung cancer","volume":"76","author":"Arbit","year":"1995","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0595","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0003-4975(90)90731-K","article-title":"Neodymium:Yag laser and brachytherapy in the management of inoperable bronchogenic carcinoma","volume":"50","author":"Miller","year":"1990","journal-title":"Ann. Thorac. Surg."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0600","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.1990.8.4.576","article-title":"The treatment of recurrent brain metastases with stereotactic radiosurgery","volume":"8","author":"Loeffler","year":"1990","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0605","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/jnci\/87.1.34","article-title":"Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases","volume":"87","author":"Alexander","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"issue":"8862","key":"10.1016\/j.bbcan.2015.08.002_bb0610","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0140-6736(93)91882-M","article-title":"Polychemotherapy in advanced non small cell lung cancer: a meta-analysis","volume":"342","author":"Souquet","year":"1993","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0615","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/bjc.1995.74","article-title":"Symptom relief with MVP (mitomycin c, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer","volume":"71","author":"Ellis","year":"1995","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0620","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.1993.497","article-title":"A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: quality of life. Medical Research Council Lung Cancer Working Party","volume":"68","author":"Bleehen","year":"1993","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0625","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1634\/theoncologist.2008-0232","article-title":"The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies","volume":"14","author":"Scagliotti","year":"2009","journal-title":"Oncologist"},{"issue":"9496","key":"10.1016\/j.bbcan.2015.08.002_bb0630","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.bbcan.2015.08.002_bb0635","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2006.05.8073","article-title":"Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21","volume":"24","author":"Bezjak","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0640","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(11)70385-0","article-title":"Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study","volume":"13","author":"Ciuleanu","year":"2012","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.bbcan.2015.08.002_bb0645","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0650","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.bbcan.2015.08.002_bb0655","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4\u2013ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0660","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11523-012-0227-8","article-title":"Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma","volume":"7","author":"La Madrid","year":"2012","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0665","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0003-4975(10)62961-X","article-title":"Second primary bronchogenic carcinoma: life-table analysis of surgical treatment","volume":"27","author":"Salerno","year":"1979","journal-title":"Ann. Thorac. Surg."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0670","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199002223220802","article-title":"A randomized trial of surgery in the treatment of single metastases to the brain","volume":"322","author":"Patchell","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0675","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jtcvs.2012.12.051","article-title":"Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer","volume":"145","author":"Hamaji","year":"2013","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0680","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11060-004-8093-6","article-title":"Brain metastases: epidemiology and pathophysiology","volume":"75","author":"Gavrilovic","year":"2005","journal-title":"J. Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0685","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0169-5002(98)00020-8","article-title":"Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?","volume":"20","author":"Kelly","year":"1998","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0690","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1556-0864(15)31569-0","article-title":"Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer?","volume":"1","author":"Shi","year":"2006","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0695","first-page":"1025","article-title":"Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group","volume":"120","author":"Cox","year":"1979","journal-title":"Am. Rev. Respir. Dis."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0700","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1378\/chest.101.5.1293","article-title":"Late survival of non-small cell lung cancer patients with brain metastases. Influence of treatment","volume":"101","author":"Chang","year":"1992","journal-title":"Chest"},{"issue":"5322","key":"10.1016\/j.bbcan.2015.08.002_bb0705","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.1.5322.15","article-title":"Intracranial metastases","volume":"1","author":"Richards","year":"1963","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bbcan.2015.08.002_bb0710","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0039-6109(16)37308-X","article-title":"Metastatic brain tumors. Results of surgical and nonsurgical treatment","volume":"44","author":"Lang","year":"1964","journal-title":"Surg. Clin. North Am."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0715","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.39.6.789","article-title":"Radiation-induced dementia in patients cured of brain metastases","volume":"39","author":"DeAngelis","year":"1989","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0720","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0360-3016(97)00154-5","article-title":"Tumor-related prognostic factors for remission of brain metastases after radiotherapy","volume":"39","author":"Nieder","year":"1997","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0725","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0360-3016(94)90558-4","article-title":"The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age","volume":"29","author":"Noordijk","year":"1994","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb0730","first-page":"1021","article-title":"Reevaluation of surgery for the treatment of brain metastases: review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques","volume":"56","author":"Paek","year":"2005","journal-title":"Neurosurgery"},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0735","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10143-004-0364-3","article-title":"Surgical treatment for brain metastases: prognostic factors and survival in 177 patients","volume":"28","author":"Stark","year":"2005","journal-title":"Neurosurg. Rev."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0740","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3171\/jns.1993.79.2.0210","article-title":"Surgical treatment of multiple brain metastases","volume":"79","author":"Bindal","year":"1993","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0745","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0360-3016(98)90026-8","article-title":"Brain metastases: results and effects of re-irradiation","volume":"15","author":"Hazuka","year":"1988","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0750","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ccr.2005.07.014","article-title":"Engaging the vascular component of the tumor response","volume":"8","author":"Fuks","year":"2005","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0755","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ t cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"issue":"5622","key":"10.1016\/j.bbcan.2015.08.002_bb0760","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.1082504","article-title":"Tumor response to radiotherapy regulated by endothelial cell apoptosis","volume":"300","author":"Garcia-Barros","year":"2003","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.bbcan.2015.08.002_bb0765","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMct0806951","article-title":"Stereotactic radiosurgery for the management of brain metastases","volume":"362","author":"Suh","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0770","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11910-009-0033-6","article-title":"Management of brain metastases","volume":"9","author":"Suh","year":"2009","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0775","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0169-5002(02)00030-2","article-title":"Treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) by stereotactic linac-based radiosurgery: prognostic factors","volume":"37","author":"Zabel","year":"2002","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2015.08.002_bb0780","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/(SICI)1097-0142(19971201)80:11<2075::AID-CNCR6>3.0.CO;2-W","article-title":"Stereotactic radiosurgery for patients with nonsmall cell lung carcinoma metastatic to the brain","volume":"80","author":"Kim","year":"1997","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0785","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1005958215384","article-title":"Stereotactic radiosurgery for brain metastases: comparison of lung carcinoma vs. non-lung tumors","volume":"37","author":"Williams","year":"1998","journal-title":"J. Neuro-Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0790","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3171\/jns.2002.97.6.1276","article-title":"Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control","volume":"97","author":"Sheehan","year":"2002","journal-title":"J. Neurosurg."},{"issue":"102 Suppl.","key":"10.1016\/j.bbcan.2015.08.002_bb0795","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3171\/jns.2005.102.s_supplement.0247","article-title":"Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors","author":"Sheehan","year":"2005","journal-title":"J. Neurosurg."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0800","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1269\/jrr.90130","article-title":"Outcome of stereotactic radiosurgery for patients with non-small cell lung cancer metastatic to the brain","volume":"51","author":"Mariya","year":"2010","journal-title":"J. Radiat. Res."},{"issue":"9422","key":"10.1016\/j.bbcan.2015.08.002_bb0805","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0810","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0360-3016(99)00198-4","article-title":"Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases","volume":"45","author":"Kondziolka","year":"1999","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0815","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.3390\/cancers2042100","article-title":"Treatment of brain metastasis from lung cancer","volume":"2","author":"Chi","year":"2010","journal-title":"Cancers"},{"issue":"21","key":"10.1016\/j.bbcan.2015.08.002_bb0820","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2015.08.002_bb0825","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1016\/j.lungcan.2004.07.967","article-title":"Treatment of brain metastases from lung cancer: chemotherapy","volume":"45","author":"Schuette","year":"2004","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0830","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0360-3016(91)90137-S","article-title":"A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916)","volume":"20","author":"Komarnicky","year":"1991","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0835","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0360-3016(95)00168-X","article-title":"Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05","volume":"33","author":"Phillips","year":"1995","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0840","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1227\/00006123-199102000-00005","article-title":"Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study","volume":"28","author":"Ushio","year":"1991","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0845","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1023\/A:1008338312647","article-title":"Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1","volume":"12","author":"Robinet","year":"2001","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb0850","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bjc.6604835","article-title":"A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer","volume":"100","author":"Neuhaus","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0855","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.lungcan.2004.02.019","article-title":"A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung","volume":"46","author":"Guerrieri","year":"2004","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0860","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ijrobp.2008.05.068","article-title":"Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial","volume":"73","author":"Mehta","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0865","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2004.00.1768","article-title":"Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases","volume":"24","author":"Suh","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0870","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijrobp.2004.04.061","article-title":"Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial","volume":"61","author":"Verger","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"17","key":"10.1016\/j.bbcan.2015.08.002_bb0875","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2002.04.140","article-title":"Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases","volume":"20","author":"Antonadou","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0880","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2012.02.004","article-title":"Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions","volume":"84","author":"Ellis","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"24","key":"10.1016\/j.bbcan.2015.08.002_bb0885","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel\u2013carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2015.08.002_bb0890","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2008.16.2412","article-title":"Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab","volume":"27","author":"Sandler","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2015.08.002_bb0895","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1097\/JTO.0b013e3181da36f4","article-title":"Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel\/carboplatin for advanced non-small cell lung cancer","volume":"5","author":"Sandler","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0900","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/JTO.0b013e3181c7307e","article-title":"Safety and efficacy of combining sunitinib with bevacizumab+paclitaxel\/carboplatin in non-small cell lung cancer","volume":"5","author":"Socinski","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb0905","first-page":"354","article-title":"Randomized phase II study of sunitinib (SU) plus erlotinib (E) for the treatment of advanced\/metastatic nonsmall cell lung cancer (NSCLC)","volume":"5","author":"Groen HJM","year":"2010","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2015.08.002_bb0910","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1158\/0008-5472.CAN-07-6307","article-title":"Bibf 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy","volume":"68","author":"Hilberg","year":"2008","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0915","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/annonc\/mdq618","article-title":"A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer","volume":"22","author":"Reck","year":"2011","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb0920","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic\u2013pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb0925","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1096\/fj.07-098038","article-title":"Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells","volume":"22","author":"Spadaro","year":"2008","journal-title":"FASEB J."},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb0930","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S1470-2045(12)70126-2","article-title":"Immunotherapies for non-small-cell lung cancer and mesothelioma","volume":"13","author":"Thomas","year":"2012","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0935","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ijc.20271","article-title":"Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy","volume":"111","author":"Varadhachary","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb0940","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/JTO.0b013e3182156250","article-title":"A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer","volume":"6","author":"Digumarti","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"33","key":"10.1016\/j.bbcan.2015.08.002_bb0945","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1200\/JCO.2009.27.5040","article-title":"Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer","volume":"28","author":"Maki","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"72 Suppl 1","key":"10.1016\/j.bbcan.2015.08.002_bb0950","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/1163028-S0-000000000-00000","article-title":"Emerging new agents for the management of patients with non-small cell lung cancer","author":"Capelletto","year":"2012","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb0955","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1096-6374(02)00017-5","article-title":"Control of cell survival by IGF signaling pathways","volume":"12","author":"Vincent","year":"2002","journal-title":"Growth Hormon. IGF Res."},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2015.08.002_bb0960","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11864-010-0120-6","article-title":"Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and HH","volume":"11","author":"Neal","year":"2010","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2015.08.002_bb0965","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrc2536","article-title":"Insulin and insulin-like growth factor signalling in neoplasia","volume":"8","author":"Pollak","year":"2008","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0970","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.lungcan.2009.10.012","article-title":"Targeted therapies for non-small cell lung cancer","volume":"67","author":"Dempke","year":"2010","journal-title":"Lung Cancer"},{"issue":"15","key":"10.1016\/j.bbcan.2015.08.002_bb0975","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2008.19.9331","article-title":"Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer","volume":"27","author":"Karp","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"7500","key":"10.1016\/j.bbcan.2015.08.002_bb0980","article-title":"Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC)","volume":"28","author":"Jassem","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb0985","series-title":"Pfizer discontinues a phase 3 study of figitumumab in previously treated patients with advanced non-small cell lung cancer [media release]","year":"2010"},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb0990","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb0995","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2015.08.002_bb1000","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1158\/1078-0432.CCR-08-2787","article-title":"Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications","volume":"15","author":"Schrump","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb1005","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ijc.24759","article-title":"Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells","volume":"126","author":"Owonikoko","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb1010","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2009.24.9094","article-title":"Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer","volume":"28","author":"Ramalingam","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 7(2)","key":"10.1016\/j.bbcan.2015.08.002_bb1015","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1359-6349(09)71720-3","article-title":"Randomised, double-blind, phase II\u2013III study of first line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small cell lung cancer (NSCLC)","author":"Belani","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/JTO.0b013e318194fae7","article-title":"Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines","volume":"4","author":"Zhang","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3816\/CLC.2004.n.025","article-title":"Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies","volume":"6","author":"Haura","year":"2004","journal-title":"Clin. Lung Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2015.08.002_bb1030","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1200\/JCO.2006.08.8898","article-title":"Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1","volume":"25","author":"Tolcher","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb1035","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lungcan.2007.12.011","article-title":"Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer","volume":"61","author":"Greco","year":"2008","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb1040","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cllc.2013.12.005","article-title":"Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"15","author":"von Pawel","year":"2014","journal-title":"Clin. Lung Cancer"},{"issue":"23","key":"10.1016\/j.bbcan.2015.08.002_bb1045","doi-asserted-by":"crossref","first-page":"7733","DOI":"10.1158\/1078-0432.CCR-08-0670","article-title":"Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival","volume":"14","author":"Jin","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2015.08.002_bb1050","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1093\/annonc\/mdt249","article-title":"A phase I\/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"24","author":"Kelly","year":"2013","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb1055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/JTO.0b013e31827ce554","article-title":"A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer","volume":"8","author":"Paz-Ares","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb1060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat. Rev. Immunol."},{"issue":"17","key":"10.1016\/j.bbcan.2015.08.002_bb1065","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb1070","first-page":"27","article-title":"Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best-supportive care (BSC) following first-line platinum-based therapy in patients (PTS) with advanced non-small cell lung cancer (NSCLC)","author":"Zatloukal","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2015.08.002_bb1075","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb1080","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb1085","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1084\/jem.20051776","article-title":"Tissue expression of PD-l1 mediates peripheral t cell tolerance","volume":"203","author":"Keir","year":"2006","journal-title":"J. Exp. Med."},{"issue":"5502","key":"10.1016\/j.bbcan.2015.08.002_bb1090","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb1100","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/intimm\/dxm057","article-title":"PD-1 and PD-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int. Immunol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb1105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"19","key":"10.1016\/j.bbcan.2015.08.002_bb1110","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb1115","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb1120","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-l1\/B7h-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res."},{"issue":"127","key":"10.1016\/j.bbcan.2015.08.002_bb1125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003689","article-title":"Colocalization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape","volume":"4","author":"Taube","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"36","key":"10.1016\/j.bbcan.2015.08.002_bb1130","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1200\/JCO.2011.38.0899","article-title":"Cancer immunotherapy comes of age","volume":"29","author":"Topalian","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.bbcan.2015.08.002_bb1135","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/1758834014567470","article-title":"Nivolumab in NSCLC: latest evidence and clinical potential","volume":"7","author":"Sundar","year":"2015","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb1145","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8009","article-title":"A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC)","volume":"33","author":"Spigel","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb1150","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.18_suppl.lba109","article-title":"Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC)","volume":"33","author":"Paz-Ares","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb1155","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-l1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D'Incecco","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2015.08.002_bb1160","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb1165","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.cllc.2015.02.002","article-title":"Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma","volume":"16","author":"Lin","year":"2015","journal-title":"Clin. Lung Cancer"},{"issue":"15","key":"10.1016\/j.bbcan.2015.08.002_bb1170","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1158\/0008-5472.CAN-13-2685","article-title":"Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors","volume":"74","author":"Fu","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb1175","first-page":"408","article-title":"A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer\u2014the anti-PDL1 antibody-MEDI4736","volume":"3","author":"Lee","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"issue":"6230","key":"10.1016\/j.bbcan.2015.08.002_bb1180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb1185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet. Gynecol."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb1190","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.bbcan.2015.08.002_bb1195","first-page":"5476","article-title":"Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin","volume":"47","author":"Burchell","year":"1987","journal-title":"Cancer Res."},{"issue":"15 Pt 2","key":"10.1016\/j.bbcan.2015.08.002_bb1200","doi-asserted-by":"crossref","first-page":"s4652","DOI":"10.1158\/1078-0432.CCR-07-0213","article-title":"L-BLP25: a peptide vaccine strategy in non small cell lung cancer","volume":"13","author":"Sangha","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2015.08.002_bb1205","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00432-011-1003-3","article-title":"Updated survival analysis in patients with stage IIIb or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial","volume":"137","author":"Butts","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb1210","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JTO.0b013e31817c6b4f","article-title":"A phase II study of TG4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III\/IV non-small cell lung cancer","volume":"3","author":"Ramlau","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb1215","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/107327481302000105","article-title":"Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer","volume":"20","author":"Hall","year":"2013","journal-title":"Cancer Control"},{"issue":"12","key":"10.1016\/j.bbcan.2015.08.002_bb1220","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1470-2045(11)70259-5","article-title":"Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial","volume":"12","author":"Quoix","year":"2011","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb1225","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1023\/A:1008261031034","article-title":"A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial","volume":"9","author":"Gonzalez","year":"1998","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb1230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.37757\/MR2010.V12.N1.4","article-title":"Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy","volume":"12","author":"Rodriguez","year":"2010","journal-title":"MEDICC Rev."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4161\/cbt.5.2.2334","article-title":"Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a phase I trial","volume":"5","author":"Ramos","year":"2006","journal-title":"Cancer Biol. Ther."},{"issue":"9","key":"10.1016\/j.bbcan.2015.08.002_bb1240","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1200\/JCO.2007.11.5980","article-title":"Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer","volume":"26","author":"Neninger Vinageras","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.bbcan.2015.08.002_bb1245","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1158\/1078-0432.CCR-05-1203","article-title":"Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer","volume":"11","author":"Gure","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb1250","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejcts.2003.09.015","article-title":"Melanoma associated antigen (MAGE)-a3 expression in stages I and II non-small cell lung cancer: results of a multi-center study","volume":"25","author":"Sienel","year":"2004","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.bbcan.2015.08.002_bb1255","first-page":"55","article-title":"Phase II randomized study of MAGE-a3 immunotherapy as adjuvant therapy in stage Ib\/II non-small cell lung cancer (NSCLC): 44month follow-up, humoral and cellular immune response data","volume":"3","author":"Vansteenkiste","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb1260","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.7501","article-title":"Association of gene expression signature and clinical efficacy of MAGE-a3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage Ib\/II non-small cell lung cancer (NSCLC)","volume":"26","author":"Vansteenkiste","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb1265","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PPO.0b013e3181eacbd8","article-title":"Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy","volume":"16","author":"Gajewski","year":"2010","journal-title":"Cancer J."},{"issue":"10","key":"10.1016\/j.bbcan.2015.08.002_bb1270","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.4049\/jimmunol.136.10.3916","article-title":"Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness","volume":"136","author":"Rook","year":"1986","journal-title":"J. Immunol."},{"issue":"29","key":"10.1016\/j.bbcan.2015.08.002_bb1275","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1200\/JCO.2005.05.5335","article-title":"Phase II study of belagenpumatucel-l, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer","volume":"24","author":"Nemunaitis","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1280","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2009.04.010","article-title":"Identification of genes associated with non-small-cell lung cancer promotion and progression","volume":"67","author":"Bankovic","year":"2010","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb1285","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2005.07.003","article-title":"The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling","volume":"122","author":"Epping","year":"2005","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.bbcan.2015.08.002_bb1290","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1158\/1078-0432.CCR-03-0813","article-title":"The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome","volume":"10","author":"Oberthuer","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2015.08.002_bb1295","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ncponc0591","article-title":"Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial","volume":"3","author":"Bogaerts","year":"2006","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1300","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-007-9643-3","article-title":"Prevalence and prognostic and predictive relevance of PRAME in breast cancer","volume":"109","author":"Doolan","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb1305","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/sj.bjc.6604494","article-title":"PRAME expression and clinical outcome of breast cancer","volume":"99","author":"Epping","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2015.08.002_bb1310","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.leukres.2007.02.016","article-title":"Epigenetic regulation of PRAME gene in chronic myeloid leukemia","volume":"31","author":"Roman-Gomez","year":"2007","journal-title":"Leuk. Res."},{"issue":"28","key":"10.1016\/j.bbcan.2015.08.002_bb1315","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb1320","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/978-1-4614-6176-0_18","article-title":"Small-cell lung cancer: an update on targeted therapies","volume":"779","author":"Joshi","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.bbcan.2015.08.002_bb1325","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1200\/JCO.1990.8.3.396","article-title":"Ten-year survival of patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation","volume":"8","author":"Johnson","year":"1990","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2015.08.002_bb1330","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/(SICI)1097-0142(19960501)77:9<1947::AID-CNCR27>3.0.CO;2-Z","article-title":"The National Cancer Data Base report on lung cancer","volume":"77","author":"Fry","year":"1996","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2015.08.002_bb1335","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.1995.13.5.1215","article-title":"Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+years\u2014an analysis of 1,714 consecutive patients","volume":"13","author":"Lassen","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb1340","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb1345","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/cncr.10841","article-title":"Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America","volume":"95","author":"Janne","year":"2002","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb1350","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1056\/NEJM199908123410703","article-title":"Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group","volume":"341","author":"Auperin","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb1355","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb1360","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2003.10.089","article-title":"Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival","volume":"21","author":"Videtic","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.bbcan.2015.08.002_bb1365","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199212033272302","article-title":"A meta-analysis of thoracic radiotherapy for small-cell lung cancer","volume":"327","author":"Pignon","year":"1992","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb1370","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.1992.10.6.890","article-title":"Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis","volume":"10","author":"Warde","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.bbcan.2015.08.002_bb1375","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1056\/NEJM198704093161504","article-title":"Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung","volume":"316","author":"Perry","year":"1987","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.bbcan.2015.08.002_bb1380","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1200\/JCO.2002.12.071","article-title":"Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104","volume":"20","author":"Takada","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.bbcan.2015.08.002_bb1385","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1200\/JCO.2011.35.6923","article-title":"Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study","volume":"29","author":"Ready","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.bbcan.2015.08.002_bb1390","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1200\/JCO.2009.23.7545","article-title":"Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group study e3501","volume":"27","author":"Horn","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2015.08.002_bb1395","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/JTO.0b013e3181f0bd78","article-title":"Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial","volume":"5","author":"Gitlitz","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"19","key":"10.1016\/j.bbcan.2015.08.002_bb1400","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1158\/1078-0432.CCR-08-0332","article-title":"Epidermal growth factor receptor mutations in small cell lung cancer","volume":"14","author":"Tatematsu","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2015.08.002_bb1405","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2005.12.002","article-title":"Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group Phase II Trial","volume":"52","author":"Moore","year":"2006","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb1410","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/01.JTO.0000263714.46449.4c","article-title":"Phase II trial with carboplatin and bendamustine in patients with extensive stage small-cell lung cancer","volume":"2","author":"Koster","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"2011","key":"10.1016\/j.bbcan.2015.08.002_bb1415","article-title":"A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)","volume":"29","author":"Venepalli","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb1420","first-page":"1319","article-title":"Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette\u2013Guerin","volume":"5","author":"Grant","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"28","key":"10.1016\/j.bbcan.2015.08.002_bb1425","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1200\/JCO.2005.17.186","article-title":"Phase III study of adjuvant vaccination with Bec2\/bacille Calmette\u2013Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971b; Silva Study)","volume":"23","author":"Giaccone","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2015.08.002_bb1430","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14712598.2010.484801","article-title":"INGN-225: a dendritic cell-based p53 vaccine (ad.P53-dc) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect","volume":"10","author":"Chiappori","year":"2010","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"79 Electronic Suppl 1","key":"10.1016\/j.bbcan.2015.08.002_bb1435","doi-asserted-by":"crossref","first-page":"eS51","DOI":"10.3949\/ccjm.79.s2.11","article-title":"The emerging role of palliative medicine in the treatment of lung cancer patients","author":"Davis","year":"2012","journal-title":"Cleve. Clin. J. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb1440","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00520-009-0739-7","article-title":"Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial","volume":"18","author":"Navari","year":"2010","journal-title":"Support. Care Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2015.08.002_bb1445","first-page":"919","article-title":"Malignant mesothelioma of the pleural space","volume":"13","author":"Grondin","year":"1999","journal-title":"Oncology (Williston Park)"},{"issue":"45 Suppl 1","key":"10.1016\/j.bbcan.2015.08.002_bb1450","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.lungcan.2004.04.010","article-title":"Epidemiology of malignant mesothelioma in Australia","author":"Musk","year":"2004","journal-title":"Lung Cancer"},{"issue":"15","key":"10.1016\/j.bbcan.2015.08.002_bb1455","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"21 Suppl 5","key":"10.1016\/j.bbcan.2015.08.002_bb1460","doi-asserted-by":"crossref","first-page":"v126","DOI":"10.1093\/annonc\/mdq173","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"Stahel","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2015.08.002_bb1465","series-title":"Cancer: Principles and Practice of Oncology","article-title":"Benign and malignant mesothelioma","author":"Pass","year":"2008"},{"issue":"4","key":"10.1016\/j.bbcan.2015.08.002_bb1470","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MCP.0b013e328302851d","article-title":"Malignant mesothelioma 2008","volume":"14","author":"Zervos","year":"2008","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1475","first-page":"32","article-title":"Peritoneal mesothelioma: a review","volume":"9","author":"Bridda","year":"2007","journal-title":"MedGenMed"},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1480","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ejcts.2007.09.044","article-title":"Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients","volume":"33","author":"Borasio","year":"2008","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1485","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1053\/j.semtcvs.2009.07.005","article-title":"Multimodality management of malignant pleural mesothelioma: introduction","volume":"21","author":"Sugarbaker","year":"2009","journal-title":"Semin. Thorac. Cardiovasc. Surg."},{"issue":"14","key":"10.1016\/j.bbcan.2015.08.002_bb1490","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2\u20133","key":"10.1016\/j.bbcan.2015.08.002_bb1495","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis","volume":"9","author":"Yang","year":"2008","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb1500","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1073\/pnas.0711741105","article-title":"Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity","volume":"105","author":"Tsai","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1505","first-page":"105","article-title":"Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies","volume":"1786","author":"Singer","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"issue":"16","key":"10.1016\/j.bbcan.2015.08.002_bb1510","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.2165\/10489100-000000000-00000","article-title":"Gefitinib: a review of its use in the treatment of locally advanced\/metastatic non-small cell lung cancer","volume":"69","author":"Sanford","year":"2009","journal-title":"Drugs"},{"issue":"23","key":"10.1016\/j.bbcan.2015.08.002_bb1515","doi-asserted-by":"crossref","first-page":"11100","DOI":"10.1158\/0008-5472.CAN-06-2554","article-title":"Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885","volume":"66","author":"King","year":"2006","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2015.08.002_bb1520","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12185-010-0531-y","article-title":"The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases","volume":"91","author":"Hitoshi","year":"2010","journal-title":"Int. J. Hematol."},{"issue":"8","key":"10.1016\/j.bbcan.2015.08.002_bb1525","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2174\/156800908786733504","article-title":"The PIK3CA gene as a mutated target for cancer therapy","volume":"8","author":"Gustin","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"issue":"10","key":"10.1016\/j.bbcan.2015.08.002_bb1530","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/leu.2009.111","article-title":"Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia","volume":"23","author":"Giles","year":"2009","journal-title":"Leukemia"},{"issue":"1 Suppl 1","key":"10.1016\/j.bbcan.2015.08.002_bb1535","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminoncol.2007.12.002","article-title":"Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia","volume":"35","author":"Giles","year":"2008","journal-title":"Semin. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2015.08.002_bb1540","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00262-010-0871-8","article-title":"WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer","volume":"59","author":"Krug","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"2011","key":"10.1016\/j.bbcan.2015.08.002_bb1545","article-title":"Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM)","volume":"29","author":"Krug","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bbcan.2015.08.002_bb1550","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2014","key":"10.1016\/j.bbcan.2015.08.002_bb1555","article-title":"Dendritic cell vaccination in malignant pleural mesothelioma: a phase I\/II study","volume":"32","author":"Berneman","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X15000669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X15000669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T03:24:56Z","timestamp":1691897096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X15000669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":311,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0304419X15000669"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2015.08.002","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung cancer: Biology and treatment options","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2015.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}